Get the Daily Brief
Latest Biotech News
Bavarian Nordic Acquisition Talks Trigger $3 Billion Bid
Vaccine manufacturer Bavarian Nordic has agreed to be acquired by a consortium led by private equity firms Nordic Capital and Permira in an all-cash deal valued at approximately $3 billion. The...
GSK Inks $500M Upfront Deal with Hengrui Pharma for COPD Pipeline
GlaxoSmithKline (GSK) has agreed to a licensing deal worth $500 million upfront with China’s Jiangsu Hengrui Pharmaceuticals, acquiring rights to an experimental COPD drug and options on 11 other...
Abivax Shares Surge Following Phase III Ulcerative Colitis Data
Abivax's oral ulcerative colitis drug obefazimod surpassed expectations in Phase III trials, prompting a Nasdaq offering that was oversubscribed fivefold and raised nearly $750 million. CEO Marc...
MapLight Raises $373 Million to Advance CNS Drug Pipeline
California biotech MapLight Therapeutics secured a $372.5 million Series D financing round, one of the largest private funding events in 2025. The capital will support development of CNS drug...
FDA and Safety Scrutiny Surround Sarepta’s Duchenne Gene Therapy
The FDA is investigating the death of an 8-year-old Brazilian boy treated with Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys, following previous patient fatalities linked...
Celcuity Breast Cancer Drug Surpasses Phase 3 Endpoints
Celcuity's experimental breast cancer combination therapy achieved its primary endpoints in a Phase 3 trial, setting the stage for an FDA filing anticipated in Q4. The trial results position...
Revvity Reports 4% Revenue Growth, Raises Annual Guidance Slightly
Revvity announced 4% year-over-year revenue growth in Q2 2025, driven by gains in diagnostics and life sciences segments. Revenues totaled $720.3 million, beating estimates, with diagnostics up 3%...
Promega and Longhorn Form Co-Marketing Pact for Testing Platforms
Promega and Longhorn Vaccines and Diagnostics signed a collaboration to co-market Longhorn's PrimeStore molecular transport media with Promega's Maxwell nucleic acid extraction platforms. This...
Optogenetic Platform RELISR Controls Protein and mRNA in Cells
A KAIST research team developed RELISR, an optogenetic platform enabling precise spatiotemporal control over the storage and release of proteins and mRNAs in living cells and animals. This...
Atai Shifts Focus After Schizophrenia Drug Failure
Atai Life Sciences' subsidiary Recognify Life Sciences experienced a setback when its schizophrenia drug candidate, inidascamine, failed to meet the primary cognitive improvement endpoint in a...
Natera’s Signatera Drives Market Leadership in MRD Testing
Natera attracted Evercore ISI’s Outperform rating and a $170 price target on recognition of its leading position in the minimal residual disease (MRD) detection market through its Signatera test....
Revvity Posts 4% Revenue Growth Fueled by Diagnostics and Life Sciences
Revvity reported a 4% year-over-year increase in second-quarter revenues to $720.3 million, driven by growth in diagnostics and life sciences sectors. Diagnostics revenue rose 3% amid...
GSK Invests $500M in Hengrui to Expand COPD Pipeline
GlaxoSmithKline (GSK) agreed to pay $500 million upfront for rights to a clinical-stage COPD drug, HRS-9821, from Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals. The transaction is...
Celcuity’s Phase 3 Breast Cancer Combo Nears FDA Submission
Celcuity reported successful Phase 3 trial results for its breast cancer combination therapy gedatolisib, which delayed tumor progression and met primary endpoints in relevant patient populations....
Abivax Shares Surge on Ulcerative Colitis Phase 3 Data and Fundraising
Abivax energized investor interest after reporting strong Phase 3 data for its oral ulcerative colitis candidate obefazimod, exceeding prior expectations. The company successfully launched a...
FDA Rejection Signals Changing Oncology Regulatory Landscape for RP1
The FDA issued a complete response letter for Replimune’s RP1 oncolytic virus therapy, leading to a rapid 75% stock plunge. RP1 is an immuno-oncology candidate targeting anti-PD-1 refractory...
Mass Ivermectin Use Cuts Malaria Transmission in Kenya Trial
The BOHEMIA trial demonstrated a 26% reduction in new malaria infections following mass administration of ivermectin to children aged 5–15 in Kenya, complementing bed net use. Ivermectin’s...
Re-Vana and Boehringer Ink $1B Pact for Eye Drug Delivery Tech
Boehringer Ingelheim entered a collaboration agreement with Re-Vana Therapeutics centered on Re-Vana’s ocular extended-release drug delivery platform aimed at reducing injection frequency for...
New Insights into Mitophagy Pathways Open Parkinson’s Therapy Avenues
University of Vienna researchers elucidated distinct mechanisms by which transmembrane cargo receptors initiate mitophagy, the selective degradation of mitochondria linked to neurodegenerative...
GSK’s $12B Deal: China’s Hengrui Powers COPD Pipeline
GSK has entered a sweeping licensing agreement with China's Jiangsu Hengrui Pharmaceuticals worth up to $12 billion, including a $500 million upfront payment. The deal covers 12 drug programs...